In CRC, the methylation status of multiple promoters can be predicted through knowledge of BRAF and, to a lesser extent, KRAS activating mutations, indicating that these mutations are closely ...

Using AI, we identified publications that likely reported a testing or mutation rate, filtered publications for cancer type, and identified sentences that likely reported rates. Rates and covariates ...

SAN FRANCISCO -- First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant metastatic colorectal cancer (mCRC), according to the BREAKWATER ...

Phase III trial results supported recent FDA approval for patients with BRAF V600E mutations Data from this multi-institutional collaboration across 28 countries supported the accelerated approval of ...

Dr. Scott Kopetz discusses the BREAKWATER trial investigating Braftovi and Erbitux plus chemo in those with BRAF V600E+ metastatic colorectal cancer. Among patients with BRAF V600E-mutant metastatic ...

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its self-developed CDH17-targeting ADC (R&D code: 7MW4911) received IND clearance from the ...

While the rates of metastatic melanoma are on the rise—particularly in younger people—TIL (tumor-infiltrating lymphocyte) therapy at Fox Chase Cancer Center is a high-risk, high-reward therapy for ...

Hairy-cell leukemia (HCL) is a rare, indolent neoplasm of mature B cells with hairlike surface projections that circulate in the blood and preferentially infiltrate the bone marrow and spleen. The ...